

****Published February 2017****

MarketVIEW: Dengue vaccines (CAT: VAMV025)

Product Name	:	MarketVIEW: Dengue vaccines
Description	:	Dengue vaccines global commercial analysis
Contents	:	Executive presentation (.pdf) + 2 MS Excel workbooks (.xls)
Therapeutic Area	:	Endemic vaccines
Publication date	:	February 2017
Catalogue No	:	VAMV025

Background

Dengue fever (DF) is a mosquito-borne disease (*Aedes*) caused by single strand RNA viruses of the family *flaviviridae*. Two fifths of the world's population are thought to be at risk from DF, mainly urban dwellers in tropical and sub-tropical countries. The disease has a wide spectrum of symptoms ranging from a mild febrile illness to severe outcomes such as hospitalization and death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Importantly, of the 22,000 estimated deaths per year, the large majority are in children (< 15yrs). No specific treatment is available.

A Sanofi Pasteur vaccine (**CYD-TDV, Dengvaxia**) has been licensed since 2015 for the prevention of disease caused by all four dengue virus serotypes in preadolescents, adolescents and adults, 9 to 45 years of age living in endemic areas. In April 2016, the WHO SAGE committee recommended countries consider introduction of CYD-TDV only in geographic settings (national or subnational) with high endemicity, as indicated by seroprevalence of approximately 70% or greater. Two countries: Brazil (Parana state) and the Philippines have stated mass immunization programs, albeit with some controversy. Other dengue vaccines notably, **DenVAX (TAK-003)** (Takeda Vaccines) and **TetraVAX-DV** (NIAID, Butantan) are in late stage development.

This **MarketVIEW** product consists of a detailed Executive presentation (~135 slides, .pdf) and comprehensive MS-Excel workbooks (.xls) which forecast the potential commercial value of dengue fever vaccine(s) by competitor across 32 endemic markets to 2030. The model(s) contain value (\$ m) and volume (mio doses) predictions (public and private sector) in relevant age segments e.g. 9 yrs, 15-27/44 yrs. **LO, BASE** and **HI** forecast scenarios include expected demand from selected country catch-up campaigns and expected approvals from 2016 onwards. An intra state or region roll-out analysis is also included for Brazil and Philippines. Competitor vaccines are described in some detail with launch, market share and pricing predictions. A global review of latest disease dynamics, expert comment and epidemiology is also presented.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to dengue global epidemiology, vaccine development, competitive environment, recommendations, policy. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings (IDweek 2016), news articles, expert comment etc.

PRODUCT CONTENTS:

Published February 2017 (CAT No: VAMV025)

****This product is composed of [two MS Excel workbooks](#)¹ and [an Executive presentation \(.pdf\)](#)²

Table of Contents
Executive summary
Authors note
Commercial model - Key outputs
Dengue vaccines: potential market per scenario (\$ 000s) to 2030
Dengue vaccines: potential volumes per scenario (000s) to 2030
Dengue vaccines: Brazil market per scenario (\$ 000s) to 2030
Dengue vaccines: Brazil volume per scenario (000s) to 2030
Dengue vaccines: Philippine market per scenario (\$ 000s) to 2030
Dengue vaccines: Philippine volumes per scenario (000s) to 2030
Dengue vaccines: potential volumes/value per country (000s), 2025
Dengvaxia: potential market per scenario (\$ 000s) to 2030
DenVAX: potential market per scenario (\$ 000s) to 2030
TetraVAX: potential market per scenario (\$ 000s) to 2030
Dengvaxia: revenues (public) per country – 5 yrs post launch
DenVAX: revenues (public) per country – 5 yrs post launch
TetraVAX: revenues (public) per country – 5 yrs post launch
Brazil, India and Vietnam - TetraVAX price sensitivity analysis
Competitor summary
Dengue vaccines: private market (\$ 000s) to 2030
Dengue: background and epidemiology
Dengue: disease background
Dengue: transmission
Manifestations of dengue infection
Classification of dengue and levels of severity
Clinical comparison of dengue, chikungunya and Zika
Epidemiology: the global problem of dengue
Dengue versus other mosquito borne viruses
Distribution of dengue, Americas and Caribbean
Distribution of dengue, Africa and Middle East
Distribution of dengue, Asia and Oceania
Change in distribution of dengue serotypes
Dengue: average annual number of cases 1955 – 2007
Dengue: total cases reported per WHO region 2000 – 2010
Dengue: cumulative cases/deaths reported per WHO region 2000 – 2015
PAHO region: country ranking by cumulative cases 2000-2015
Focus on PAHO region 2011- 2015

¹ Model contents available on request

² Presentation titles may apply to more than one slide

Continued.....

SEA region: country ranking by cumulative cases 2000-2015
WPR region: country ranking by cumulative cases 2000-2015
Dengue endemic countries: rankings by cumulative reported cases
Dengue endemic countries: rankings by incidence
Top 10 dengue endemic countries: predominant serotypes
Dengue: disability adjusted life years (DALYs), 2012
Factors contributing to the global increase of dengue
Major gaps in the knowledge of dengue disease burden
Dengue serotypes & relationship to disease symptoms
Dengue: consequences of enhanced disease
Dengue: sequence of infection
Dengue: established second infection sequences leading to DHF
Dengue: economic burden – global
Dengue: economic burden – Brazil
Estimated costs of dengue in Brazil from the public payer and societal perspectives, considering two scenarios (2013 US\$)
Dengue: economic burden – Philippines
Global strategy for dengue prevention and control
Dengvaxia (Sanofi Pasteur) – background
Dengvaxia – summary of late stage data
Sanofi Pasteur CYD: format/components
CYD/ChimeriVax™ dengue: summary of Phase III studies
Dengvaxia: efficacy and long term safety studies – design
Dengvaxia: efficacy and long term safety studies – results
Dengvaxia: disease enhancement in 2-5 yrs
Potential explanations for signal in 2-5 yrs group
WHO: SAGE recommendations - April 2016
XXIV: Technical Advisory Group (TAG)/PAHO - May 2016
WHO position paper - July 2016
Dengvaxia: need for prior immunological screening?
Dengvaxia: potential impact on Zika
Dengvaxia: Country implementation
Dengvaxia: vaccine characteristics
Dengvaxia: approval timeline 2015/2016
Dengvaxia (Sanofi Pasteur) - reported sales to date
Dengvaxia: aligning reported revenues
Dengvaxia: Brazil
Parana: mass vaccination campaign
Parana: priority areas and campaign costs
Parana campaign: controversies
Dengvaxia: Philippines
Dengvaxia: Philippines priority areas
Dengvaxia: campaign costs
Philippines campaign: controversies
Dengvaxia: expected registrations 2017 onwards
Dengue vaccines - competitive landscape: review of current R&D pipeline
Dengue vaccines - competitive landscape: major players
Dengue vaccines - competitive landscape (other clinical)
Focus on DENvax (TDV, TAK-003) – Takeda
Focus on DENvax (TAK-003) - Phase II studies
Focus on DENvax (TAK-003) - Phase II data
Focus on DENvax (TAK-003) - Phase III study (TIDES)
Focus on TV-003/Tetravax-DV
TV003 and TV005, single dose (Day 180)
Summary TV-003 and TV-005 studies
NIAID: licensing agreements summary

Continued.....

TDENV PIV – GSK
V180 – Merck & Co
Dengue vaccines: preclinical pipeline
Novel immunization strategies: NS-1
Novel immunization strategies: transmission blocking
Commercial model - Detailed assumptions per WHO region/country
Dengue vaccines: possible deployment strategies
Dengue vaccines: modelling the Brazilian market
Brazilian market: state roll-out scenarios
Dengue vaccines: modelling the Philippines market
Philippines market: region roll-out scenarios
Modelling strategy: dengue disease burden
Dengue vaccines: global rollout methodology
Global roll-out summary table (approved countries)
Global roll-out summary table (submitted countries/PAHO)
Global roll-out summary table (submitted countries/SEA/WPR)
Modelling strategy: competitor vaccines
Competitor vaccines: coverage rates (public)
Estimating competitor market share (Brazil/public)
Estimating competitor market share (PAHO/public)
Estimating competitor market share (GAVI)
Dengvaxia: willingness to pay (private market)
Dengvaxia pricing forecast
DenVAX pricing forecast
TetraVAX pricing forecast
Modelling strategy: private markets
Competitor vaccines: coverage rates (private)
Estimating competitor market share (private)
Dengue vaccine - for travellers?
Modelling strategy: boosting/compliance
Modelling caveats and limitations
Bibliography
About **VacZine Analytics**
Disclaimer

Slide number = 145

Model worksheet number = 110 x 2

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT (All deliverables) - USD **\$10995.00**/ GBP **£8795.00**# (Region license)*
- PRESENTATION ONLY - USD **\$7695.00**/ GBP **£6155.00**# (Region license)*

Indicative company rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



BIBLIOGRAPHY

1. WHO Regional Publication. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. SEARO. 2011
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution and burden of dengue. *Nature*; 496:504–507.
3. World Health Organization, Special Programme for Research,
4. Training in Tropical Diseases, et al. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. Geneva: WHO; 2009.
5. Loos S, Mallet HP, Goffart IL, et al. Current Zika virus epidemiology and recent epidemics. *Med Mal Infect*. 2014;44:302–7
6. Hales S et al (2002) Potential effect of population and climate changes on global distribution of dengue fever: an empirical model. *Lancet* 360: 830–834
7. Beatty M et al (2007) Estimating the total world population at risk for locally acquired dengue infection; Philadelphia. pp. 170–257
8. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. *PLoS Negl Trop Dis*. 2012;6:e1760. doi:10.1371/journal.pntd.0001760.
9. WHO. 10 facts on malaria. November 2015 Available at: <http://www.who.int/features/factfiles/malaria/en/>. Accessed October 2016.
10. CDC. Dengue epidemiology. Available at: <http://www.cdc.gov/dengue/epidemiology/>. Accessed October 2016.
11. WHO. Zika situation report. Zika And Potential Complications. 12 February 2016. Available at <http://www.who.int/emergencies/zika-virus/situation-report/en/>. Accessed October 2016.
12. WHO. Yellow fever. May 2016 Available at: <http://www.who.int/mediacentre/factsheets/fs100/en/> Accessed October 2016.
13. Chikungunya Virus. US Centers For Disease Control and Prevention (CDC). Geographic Distribution. Available at: <http://www.cdc.gov/chikungunya/geo/index.html>. Accessed October 2016.
14. Japanese Encephalitis. US Centers For Disease Control and Prevention (CDC). Geographic Distribution. Available at: <https://www.cdc.gov/japaneseencephalitis/> Accessed October 2016.
15. US Centers For Disease Control and Prevention. Traveler's Health. Yellow Book. Chapter 3. Dengue. Available at: <http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/dengue> Accessed November 2016
16. World Health Organisation (WHO). Dengue: prevention and control. Executive Board 136th Session. Report by the Secretariat. November 2014
17. Gubler, D. J. Dengue and dengue haemorrhagic fever. *Clin. Microbiol. Rev.* 11, 480–496 (1998).
18. World Health Organisation. Dengue – Guidelines For Diagnosis, Treatment, Prevention and Control. New Edition 2009
19. Number of reported cases of dengue and severe dengue in the Americas. PAHO. Available at: http://www.paho.org/hq/index.php?option=com_topics&view=article&id=1&Itemid=40734. Accessed November 2016
20. World Health Organisation. Regional Office for South East Asia (SEARO) Available at: http://www.searo.who.int/entity/vector_borne_tropical_diseases/data/graphs.pdf?ua=1 Accessed November 2016
21. National Vector Borne Disease Control Program. Dengue Cases and Deaths since 2010. Available at: <http://www.nvbdc.gov.in/den-cd.html> Accessed November 2016
22. World Health Organisation. Western Pacific Region. Dengue disease data. Available at http://www.wpro.who.int/emerging_diseases/DengueSituationUpdates/en/ Accessed November 2016
23. World Health Organization (WHO). The global burden of disease: 2000-12 update. Available at: http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html Accessed November 2016
24. Suaya JA., et al Dengue: Burden Of Disease And Costs Of Illness. Working Paper for the Scientific Working Group on Dengue Research, convened by the Special Programme for Research and Training in Tropical Diseases, Geneva, 1 – 5 October 2006
25. Halsey ES, Marks MA, Gotuzzo E, Fiestas V, et al. (2012) Correlation of Serotype-Specific Dengue Virus Infection with Clinical Manifestations. *PLoS Negl Trop Dis* 6(5): e1638. doi:10.1371/journal.pntd.0001638. Available at: <http://www.plosntd.org/article/info:doi/10.1371/journal.pntd.0001638>. Accessed November 2016
26. Choudri Y, Dash AP (2011) Outbreaks and public health emergencies. *World Health Organization. Communicable Disease Newsletter* 8: 2–4
27. Montoya M et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. *PLoS Negl Trop Dis* 2013; 7(8): e2357

28. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. *J Infect Dis* 181: 2–9
29. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. *Adv Virus Res* 60: 421–467
30. Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. *Yale J Biol Med* 42: 311–328.
31. Taken from: Vaughn DW., et al. *J.Infect Dis* 2000;181(1):2-9
32. Gibbons V et al. Analysis of Repeat Hospital Admissions for Dengue to Estimate the Frequency of Third or Fourth Dengue Infections Resulting in Admissions and Dengue Hemorrhagic Fever, and Serotype Sequences. *Am. J. Trop. Med. Hyg.*, 77(5), 2007 pp. 910-913
33. Shepard DS., et al. Economic impact of Dengue illness in the Americas. *Am. J. Trop. Med. Hyg.*, 84(2), 2011 pp 200-207
34. Shepard DS., et al The Global Economic burden of dengue: a systematic analysis. *The Lancet Infectious Diseases*. Vol 16, No. 8, p935-941, August 2016
35. Martelli CM, et al. Economic Impact of Dengue: Multicenter Study across Four Brazilian Regions. *PLoS Negl Trop Dis*. 2015 Sep 24;9(9):e0004042. doi: 10.1371/journal.pntd.0004042
36. Edillio FE et al. Economic Cost and Burden of Dengue in the Philippines. *Am J Trop Med Hyg*. 2015 Feb 4; 92(2): 360–366. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347342/> Accessed January 2017
37. Global strategy for dengue prevention and control, 2012–2020. World Health Organisation. 2012
38. Sanofi Pasteur Corporate Press Release. December 9, 2015. Available at: <http://www.sanofipasteur.com/en/articles/dengvaxia-world-s-first-dengue-vaccine-approved-in-mexico.aspx>. Accessed November 2015
39. Capeding M.R. et.al, Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial; Volume 384, Issue 9951, 11–17 October 2014, Pages 1358–1365
40. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. *N Engl J Med*. 2015
41. Hadinegoro, Sri Rezeki S., et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease Integrated Analysis of Efficacy and Interim Long-Term Safety Data for a Dengue Vaccine in Endemic Regions. July 27, 2015DOI: 10.1056/NEJMoa1506223
42. Guy B et al., From Research to phase III. Preclinical industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. *Vaccine* 29 (2011) 7229-7241
43. Adapted from Presentation by S.Halstead. ID week 2016, October 26-30 New Orleans, Louisiana, USA
44. Background paper on dengue vaccines. WHO secretariat. SAGE working group on dengue vaccines. 17th March 2016
45. Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. *Nat Rev Microbiol*. 2015;14:45-54.
46. Summary of the April 2016 meeting of the Strategic Advisory Group of Experts on immunization (SAGE). Available at: http://www.who.int/immunization/sage/meetings/2016/april/SAGE_April_2016_Meeting_Web_summary.pdf?ua=1. Accessed November 2016
47. Fasche S et al. Comparative modelling of dengue vaccine public health impact. Available at: http://www.who.int/immunization/sage/meetings/2016/april/2_CMDVI_Report_FINAL.pdf. Accessed November 2016
48. Ad-hoc Virtual TAG Meeting 2016. May 13, 2016. Available at: http://www.paho.org/hq/index.php?option=com_content&view=article&id=12214%3A2016-xxiv-technical-advisory-group-tag-meeting&catid=4398%3Afeatured-items&Itemid=40296&lang=en. Accessed November 2016
49. World Health Organisation (WHO). *Weekly Epidemiological Record*. 2016, 91, 349-364
50. Aguiar M et al., The risks behind Dengvaxia recommendation. *The Lancet*. Vol 16 August 2016
51. World Health Organization. Zika emergency. Available at: <http://www.who.int/mediacentre/news/statements/2016/1st-emergency-committee-zika/en/> (2016). Accessed December 2016
52. Brathwaite Dick, O. et al. The history of dengue outbreaks in the Americas. *Am. J. Trop. Med. Hyg*. 87, 584–593 (2012)
53. Castanha, P.M. et al. Force of infection of dengue serotypes in a population-based study in the northeast of Brazil. *Epidemiol. Infect.* 141, 1080–1088 (2013)
54. Braga, C. et al. Seroprevalence and risk factors for dengue infection in socio-economically distinct areas of Recife, Brazil. *Acta Trop.* 113, 234–240 (2010)
55. Screaton, G., Mongkolsapaya, J., Yacoub, S. & Roberts, C. New insights into the immunopathology and control of dengue virus infection. *Nat. Rev. Immunol.* 15, 745–759 (2015)

56. Dejnirattisai W et al. Dengue irus sero-cross-reactivity drives ADE of infection with zika virus. Nature Immunology. Vol 16. No 9. September 2016
57. Sanofi Aventis Corporate Results Presentation. Available at: http://en.sanofi.com/Images/48679_20161028_Results-2016_presentation_V2.pdf. Accessed January 2016
58. Sanofi Aventis Corporate Results Presentation. Available at: http://en.sanofi.com/Images/48382_20160729_Results-2016_presentation.pdf. Accessed January 2016
59. Sanofi Aventis Corporate Results Presentation. Available at: http://en.sanofi.com/Images/48683_20161028_Results-2016_EN.pdf. Accessed January 2016
60. Dengvaxia – first dengue vaccine approved in Brazil. Sanofi Pasteur Corporate News Release, December 28th 2015. Available at: <http://www.sanofipasteur.com/en/articles/Dengvaxia-First-Dengue-Vaccine-Approved-in-Brazil.aspx>. Accessed November 2016
61. Martelli CM, et al. Economic Impact of Dengue: Multicenter Study across Four Brazilian Regions. PLoS Negl Trop Dis. 2015 Sep 24;9(9):e0004042. doi: 10.1371/journal.pntd.0004042
62. Dengue immunization public program in Parana state of Brazil. Sanofi Pasteur Corporate News Release, August 13th 2016. Available at: <http://www.sanofipasteur.com/en/articles/Dengue-Immunization-Public-Program-in-Parana-State-of-Brazil.aspx>. Accessed November 2016
63. Denizir V A, et al. Jornal Brasileiro de Economia da Saúde Brazilian Journal of Health Economics ABRIL 2016, VOLUME 8, NÚMERO 1 | APRIL 2016, VOLUME 8, NUMBER 1
64. Richa announces dengue vaccination for 500,000 people in 30 municipalities. Available at: <http://www.casacivil.pr.gov.br/2016/07/90131,10/Richa-anuncia-vacinacao-contra-denguepara-500-mil-pessoas-em-30-municipios.html>. Accessed November 2016
65. ANVISA. National Health Surveillance Agency.
66. UOL News Article. September 2016 Available at: <https://noticias.uol.com.br/saude/ultimas-noticias/redacao/2016/09/22/vacinacao-contra-dengue-no-parana-nao-segue-recomendacao-da-oms.htm>. Accessed January 2016
67. Folha De S.Paulo News Article. September 2016 Available at: <http://www1.folha.uol.com.br/cotidiano/2016/09/1810386-com-baixa-procura-governo-do-parana-estende-vacinacao-contra-dengue.shtml> Accessed January 2016
68. Sanofi Pasteur Corporate Press Release. April 4th 2016. World's First Public Dengue Immunization Program Starts in the Philippines. Available at: <http://www.sanofipasteur.com/en/articles/World-s-First-Public-Dengue-Immunization-Program-Starts-in-the-Philippines.aspx>. Accessed November 2016
69. Asia Pacific Analysis: Philippines bet on dengue vaccine. 9th May 2016. Available at: <http://www.scidev.net/asia-pacific/health/analysis-blog/asia-pacific-analysis-philippines-bet-on-dengue-vaccine.html>. Accessed November 2016
70. Republic of Philippines. Department of Health. PH successfully launched the first dengue vaccines in public schools. April 13 2016. Available at: <http://www.doh.gov.ph/node/5716> Accessed November 2016
71. Philippine Statistics Authority. Republic of the Philippines. Available at: <http://nap.psa.gov.ph/activestats/psgc/listreg.asp>. Accessed November 2016
72. 25th Meeting of the Technical Advisory Group on Immunization and Vaccine Preventable diseases. Manila Philippines 26-29th July 2016
73. DOH to spend P3,000 per child on dengue vaccine. News article. Philstar Global Available at: <http://www.philstar.com/headlines/2016/01/11/1541365/doh-spend-p3000-child-dengue-vaccine> Accessed November 2016
74. Sanofi to launch dengue mass vaccination program. Financial Times news article, April 2016
75. Fierce Pharma News article. Jan 3 2017 Available at: <http://www.fiercepharma.com/vaccines/sanofi-must-cease-dengue-vaccine-advertising-philippine-fda-says> Accessed January 2016
76. Gulf News. Philippines. January 3rd 2017. Available at: <http://gulfnews.com/news/asia/philippines/philippines-halts-dengue-vaccine-programme-1.1955563> Accessed January 2016
77. Sanofi Aventis. Letter to shareholders, 2016. Available at: http://en.sanofi.com/Images/46626_Letter_to_shareholders_03_2016.pdf. Accessed January 2016
78. Fierce Pharma article. September 2016. Available at: <http://www.fiercepharma.com/vaccines/sanofi-dengvaxia-applications-up-to-25-countries-immunization-campaign-talks-advancing> Accessed January 2016
79. EL Tiemp News Article, 2015 Available at: <http://www.eltiempo.com/estilo-de-vida/salud/vacuna-contra-el-dengue-se-tendria-para-inicios-de-2016/16164515> Accessed January 2016

80. Malaysia outlook. Oct 5 2016 Available at: <http://www.malaysiaoutlook.com/malaysia-drags-feet-on-anti-dengue-vaccine-dengvaxia/> Accessed January 2016
81. Singapore HAS authority. Available at: http://www.hsa.gov.sg/content/hsa/en/News_Events/HSA_Updates/2016/hsa-approves-dengvaxiavaccine.html. Accessed January 2016
82. Scrip Pharma Intelligence. Available at: <https://scrip.pharmamedtechbi.com/SC097282/Local-Trials-Could-Delay-India-Dengvaxia-Rollout-By-Three-Years-Sanofi>. Accessed January 2016
83. Orellano PW et al., Cost utility of dengue vaccination in a country with heterogenous risk of dengue transmission. *Vaccine* 2016 Jan 27;34(5):616-21
84. Liu YL et al. Vaccines and immunization strategies for dengue prevention. *Emerg Microbes and Infections* (2016) 5, e77
85. Osorio JE, Huang CY-H, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. *Vaccine* 2011;29:7251-60
86. Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naïve healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. *Lancet Infect Dis* 2014;14:830-8
87. Wallace, D. (2015). Persistence of neutralizing antibodies one year after two doses of a candidate recombinant tetravalent dengue vaccine in subjects aged from 1.5 to 45 years. Presented at 6th Annual Meeting, American Society of Tropical Medicine and Hygiene
88. Saez-Llorens X., et al. (2016). Phase II, double-blind, controlled trial to assess the safety and immunogenicity of different schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in healthy subjects aged between 2 and <18 years and living in dengue endemic countries in Asia and Latin America. Presented at 5th Pan-American Dengue Research Network Meeting.
89. Takeda Pharmaceuticals. Corporate News Release, September 2016 Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003).
90. Durbin AP, McArthur J, Marron JA et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. *Hum Vaccine* 2006; 2: 167-173
91. Durbin AP, McArthur JH, Marron JA et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue naïve adults. *Hum Vaccine* 2006; 2: 255-260
92. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naïve adults: a randomized, double-blind clinical trial. *J Infect Dis* 2013;207:957-65
93. Kirkpatrick BD et al. The live attenuated dengue vaccine TV-003 elicits complete protection against dengue in the human challenge model. *Sci Trans Med* 16 Mar 2016 Vol 8, 330 pp 330
94. Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, et al. Robust and balanced immune responses to all 4 dengue virus serotypes allowing administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naïve adults. *J Infect Dis* 2015
95. Based upon SLIPE Dengue Position paper, July 2016. Available at: http://www.slipe.org/DENGUE_PositionPaper_Revision_References.pdf. Accessed December 2016
96. Rafaele et al Epidemiological scenario of dengue in Brazil. *BioMed Research International*. Vol 2015. <http://dx.doi.org/10.1155/2015/321873>
97. Dengue cases to November 2016. Republic of Philippines, Department of Health http://www.doh.gov.ph/sites/default/files/statistics/DENGUE44_compressed.pdf
98. Palanca-Tan R et al. The demand for a dengue vaccine: A contingent valuation survey in Metro Manila. *Vaccine* 2008 Vol 26, Issue 7
99. Lee JS et al. A Multi-country Study of the Household Willingness-to-Pay for Dengue Vaccines: Household Surveys in Vietnam, Thailand, and Colombia. *PLOS* 2015, <http://dx.doi.org/10.1371/journal.pntd.0003810>
100. Piassi G et al. Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil : implication for future pricing considerations. *Frontiers in Pharmacology*. ISSN 1663- 9812 (In Press) , <http://dx.doi.org/10.3389/fphar.2017.00041>

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009